Cardiorenal Consequences of Atherosclerosis and Statins Therapy: From the Past to the Future

Author(s): M. Buemi, C. Aloisi, F. Fulvio, C. Caccamo, E. Cavallaro, E. Crasci, M. Criseo, F. Corica, N. Frisina

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 30 , 2005

Become EABM
Become Reviewer


Complications from atherosclerosis cause most deaths in western countries, and their incidence appears to be markedly increasing in developing countries, thus suggesting a correlation that is directly proportional to social progress. In recent years, the different branches of medical research, from studies on vascular disease to those on lipid and glucose metabolism, and also clinical research on coronary, carotid and peripheral artery diseases, epidemiologic and pharmacologic research, have concentrated on these diseases with the common aim of reducing the incidence of cardiovascular diseases, and mortality. Scientific progress has greatly improved our understanding of the pathogenic mechanisms underlying the progression of cardiovascular disease, and efforts in this discipline now appear more necessary than ever.

Keywords: Hyperlipidemia, Endothelial Dysfunction, low density lipoproteins (LDL), C. Pneumoniae, RENAL FAILURE, IMMUNOMODULATION, NEOVASCULARIZATION

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [3973 - 3984]
Pages: 12
DOI: 10.2174/138161205774580589
Price: $65

Article Metrics

PDF: 1